Corticotropin-releasing factor pathway (CRF pathway)

The Corticotropin-releasing factor pathway is a complex neuroendocrine system that plays a pivotal role in regulating physiological responses to stress and maintaining homeostasis[1][2]. At its core, this pathway involves corticotropin-releasing factor (CRF), a 41-amino acid neuropeptide, along with related peptides called urocortins, which signal through two main G protein-coupled receptors: CRFR1 and CRFR2, both belonging to the class B1 subfamily of GPCRs[1][3]. The pathway operates primarily through the hypothalamic-pituitary-adrenal (HPA) axis, where CRF secreted from the paraventricular nucleus of the hypothalamus stimulates the anterior pituitary to release adrenocorticotropic hormone (ACTH), which in turn triggers the adrenal cortex to release glucocorticoid hormones[4][7]. These glucocorticoids exert negative feedback on the HPA axis to regulate its function. Beyond its endocrine role, CRF acts as a neuromodulator throughout the central nervous system, with CRFR1 widely expressed in regions including the cortex, cerebellum, hippocampus, and basolateral amygdala[11][15]. The molecular signaling mechanisms of CRF receptors are more complex than initially understood. Upon CRF binding, these receptors engage canonical G protein signaling through Gs proteins, activating adenylyl cyclases to produce cAMP[5]. However, research has revealed additional complexity, including endosome-based signaling involving soluble adenylyl cyclase (sAC) and sustained ERK1/2 activation that depends on receptor endocytosis and β-arrestin2[5]. The pathway also involves CRF-binding protein (CRF-BP), which physically interacts with CRFR2α and acts as an escort-like protein facilitating receptor presence at the plasma membrane while also regulating CRF bioavailability[1][4]. The CRF pathway has garnered significant attention as a therapeutic target for neuropsychiatric disorders, particularly those with stress-related components[2]. Considerable preclinical evidence supports its role in depression, PTSD, alcohol and substance use disorders, and anxiety conditions[2][4]. The system's involvement extends to memory consolidation during acute stress, with CRF rapidly enhancing synaptic communication in the hippocampus[9], and to peripheral functions including gut motor regulation[13]. Despite promising preclinical data, clinical trials of CRFR1 antagonists have met with limited therapeutic success across multiple psychiatric conditions[2][4]. This discrepancy has led researchers to explore alternative approaches, including targeting CRF-BP as a novel therapeutic strategy[4], developing drugs with dual agonist/antagonist properties that can simultaneously inhibit CRFR1 and stimulate CRFR2[6], and identifying specific patient populations, such as those with treatment-resistant depression, who may benefit from CRF-targeted therapies[6]. The unfolding complexity of the CRF system, including receptor isoform-specific functions, circuit-specific roles, and intricate signaling cascades, continues to promise new directions for understanding and treating stress-related neuropsychiatric conditions[2].

Other names

Corticotropin-releasing hormone pathwayCRH pathwayCRF systemCorticotropin-releasing factor systemHPA axis (when referring to the hypothalamic-pituitary-adrenal component)

CRFR1 antagonism to block excessive stress responses; CRFR2 agonism for potential therapeutic benefit; CRF-binding protein modulation to regulate CRF bioavailability; Dual agonist/antagonist approaches targeting both CRFR1 inhibition and CRFR2 stimulation; Modulation of G protein signaling and cAMP production; Regulation of endosome-based receptor signaling pathways.